Related Experiment Video

Updated: Nov 4, 2025

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.6K

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Alexander Bagaev1, Nikita Kotlov1, Krystle Nomie1

  • 1BostonGene, Waltham, MA 02453, USA.

Cancer Cell
|May 21, 2021
PubMed

Insights

Transcriptomic analysis reveals four tumor microenvironment (TME) subtypes across 20 cancers, acting as biomarkers for immunotherapy response. This approach aids in personalized cancer treatment by integrating genomic and transcriptomic data.

Area of Science:

  • Oncology
  • Bioinformatics
  • Cancer Genomics

Background:

  • Molecular targeted therapy predominantly relies on genomic alterations.
  • The tumor microenvironment (TME) significantly influences cancer progression and treatment outcomes.
  • Transcriptomic analysis provides a deeper understanding of tumor complexity, including the TME.

Purpose of the Study:

  • To classify TME subtypes using transcriptomic data across diverse cancer types.
  • To evaluate the correlation between TME subtypes and patient response to immunotherapy.
  • To develop a visual tool for integrating transcriptomic and genomic data for a comprehensive tumor analysis.

Main Methods:

  • Transcriptomic analysis of over 10,000 cancer patients.
  • Identification and classification of distinct TME subtypes.
  • Integration of transcriptomic and genomic data for visualization.

Main Results:

  • Four distinct TME subtypes were identified and conserved across 20 different cancer types.
  • TME subtypes correlate with patient response to immunotherapy, with immune-favorable subtypes showing greater benefit.
  • A visual tool was developed to provide a global tumor portrait, including genomic and immune characteristics.

Conclusions:

  • TME subtypes serve as a generalized immunotherapy biomarker across multiple cancer types.
  • Integrative analysis and visualization of transcriptomic and genomic data can facilitate biomarker discovery.
  • This approach supports the personalization of therapeutic regimens in cancer treatment.
Keywords:
biomarker discoverycancergenomicsintegrated analysistranscriptomicstumor microenvironment classification

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.9K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
798
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K